Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.
about
Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseasesRecommendations for the Treatment of Invasive Fungal Infections in Hematological Malignancies: A Critical Review of Evidence and Turkish Expert Opinion (TEO-1)Liposomal Formulations in Clinical Use: An Updated Review.Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats.Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosisEfficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis.Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infectionsPharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholateRandomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients.Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infectionsTolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy.Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimensTargeting bacterial membrane function: an underexploited mechanism for treating persistent infectionsLiposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.Optimizing efficacy of amphotericin B through nanomodification.High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic studyPharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose (1 mg/kg) in peripheral stem celSafety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats.New Insights Regarding Yeast Survival following Exposure to Liposomal Amphotericin B.Liposomal amphotericin B in travelers with cutaneous and muco-cutaneous leishmaniasis: Not a panacea.Increasing the Fungicidal Action of Amphotericin B by Inhibiting the Nitric Oxide-Dependent Tolerance Pathway.Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome and AmBisome in murine cutaneous leishmaniasis
P2860
Q24542404-D28F0BE7-46B5-473B-A1E7-BF52B23BAE8CQ26824260-0B298112-0734-4C61-94B9-EFB3246BD2ADQ33850427-7FA64DF4-78DB-4983-A892-6A7137FD3BA6Q33978902-A1D395A2-7D80-478B-8FED-CD1877BEE516Q33980413-B71CFF94-B51E-4FE6-9CC4-CFCE342592E8Q33980429-EB5D1B53-0C8F-49D3-A82D-FA31DAB9B811Q33983629-49647203-9B2C-42E5-B2E2-C223CDEF25A0Q34108585-C4E69F46-ED12-496B-829E-4AEDB7B0CDC8Q34113512-1DA3D34A-FB27-47DF-8980-D97A1305744EQ34113525-C8E64625-347D-4402-88B5-CF5F8E13C230Q34151170-AF5E4A30-2581-4A88-976B-59E4E6F3C4A1Q34352186-7749E479-8C1C-457D-893A-A9E81B569B4EQ35385786-9B31731E-7798-40DD-BB8B-CEBA62F3CB79Q35666527-D9C77FD1-A6D0-4ECB-8613-3EFFE52D5EC1Q35666612-D17D3494-D894-479B-9252-BA930B9624DAQ35680443-EB7CB5AD-3EA1-4D89-AC5D-D078694071F4Q36248701-A3796FDB-305D-42C6-9C6E-36A7A628B66EQ36276870-6A70E2EE-C4DE-498F-93C0-5C716519C66DQ36393640-10B23D1E-B4F4-413F-9A72-8E9F84E0EF52Q36868273-7309E5B5-E2E0-4EAA-84B6-8E52CF50E455Q36920328-F9D5D758-36F6-433A-882E-D2238B9979CAQ37016279-BDAAFCFB-66DB-4F45-B976-68F6C7ED153EQ37333175-35FC37A6-3521-4273-9EE2-4F0D4274FDDEQ37613070-F5F3A5CE-41D7-4B2D-9837-E5D770D47C6EQ38653256-97C6AB92-0E4C-4A25-AA80-5F1894C20062Q38681635-EB35C3E4-FF11-4EBB-8FF3-B3D59C412E77Q39473415-1B628A66-B313-4C77-85E7-E987DD277D92Q41066158-88AABC15-EC80-4D23-99C7-899BB0A7F181Q46258168-29084EFD-8A6C-441A-94E3-C65F12D8AAF5Q46263004-742DD872-DA6E-4C82-A8F6-B62FEB897A4CQ57952724-0D80D051-11BF-40EA-B5A7-F1E4EE5593C1
P2860
Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Safety, tolerance, and pharmac ...... some) in neutropenic patients.
@ast
Safety, tolerance, and pharmac ...... some) in neutropenic patients.
@en
type
label
Safety, tolerance, and pharmac ...... some) in neutropenic patients.
@ast
Safety, tolerance, and pharmac ...... some) in neutropenic patients.
@en
prefLabel
Safety, tolerance, and pharmac ...... some) in neutropenic patients.
@ast
Safety, tolerance, and pharmac ...... some) in neutropenic patients.
@en
P2093
P2860
P1476
Safety, tolerance, and pharmac ...... some) in neutropenic patients.
@en
P2093
A Freifeld
C Gonzalez
I Bekersky
N I Seibel
P Jarosinski
P2860
P304
P407
P577
1998-09-01T00:00:00Z